APP and neoplasm: As shown in Figure 2B, alternating oAd/APP (Day 1, 3, and 5) and DC (Day 2, 4, and 6) treatment led to combination therapy (oAd/APP+DC group) exerting significantly more potent antitumor efficacy than either DC or oAd/APP monotherapy (P < 0.01), demonstrating that combination of both therapeutics under optimal treatment schedule can induce beneficial tumor growth inhibiting effect.